68 results
8-K
EX-10.1
KPTI
Karyopharm Therapeutics Inc
14 May 24
Other Events
4:06pm
and their respective Subsidiaries and Controlled Entities.
“Commitment” means the commitment of a Lender to make or otherwise fund a Term Loan and “Commitments … ” means such commitments of all Lenders in the aggregate. The amount of each Lender’s Commitment is set forth on Appendix A. The aggregate amount
8-K
EX-4.1
KPTI
Karyopharm Therapeutics Inc
14 May 24
Other Events
4:06pm
, replacement or renewal of any Investment existing on, or made pursuant to a binding commitment existing on, the Closing Date; provided that the amount of any … letter of credit, commitment, facility, utilization, make-
whole or similar fee so that the combined interest rate and fees are increased by more than 3.0
8-K
EX-10.3
KPTI
Karyopharm Therapeutics Inc
14 May 24
Other Events
4:06pm
) or underwritten basis (whether firm commitment or otherwise) without substantial marketing efforts prior to pricing, including, without limitation, a same day
8-K
EX-10.4
KPTI
Karyopharm Therapeutics Inc
14 May 24
Other Events
4:06pm
or implement any letter of credit, commitment, facility, utilization, make-whole or similar fee so that the combined interest rate and fees are increased … , commitment, facility, utilization, make-whole or similar fee so that the combined interest rate and fees are increased by a rate that would result
8-K
EX-99.1
ohcll1adhul617
8 May 24
Entry into a Material Definitive Agreement
7:52am
8-K
EX-99.1
5fazj2sz 9imt5q
4 Aug 22
Karyopharm Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress
7:36am